Coenzyme Q10 Supplementation and Oocyte Aneuploidy in Women Undergoing IVF-ICSI Treatment.
Coenzyme Q10 Supplementation and Oocyte Aneuploidy in Women Undergoing IVF-ICSI Treatment.
复制标题
接受IVF-ISSI治疗的妇女中的辅酶Q10补充和卵母细胞倍倍性。
DOI：
10.4137/cmrh.s14681
复制
发表时间：
2014
期刊：
影响因子：
--
通讯作者：
Casper RF
中科院分区：
文献类型：
--
作者：
Bentov Y;Hannam T;Jurisicova A;Esfandiari N;Casper RF
与年龄相关的活产率下降归因于高非整倍体率和卵泡耗竭。我们在动物模型中证明，辅酶 Q10 (CoQ10) 治疗可显着改善生殖结果。本研究的目的是比较接受 CoQ10 或安慰剂治疗的体外受精 (IVF) 和胞浆内单精子注射 (ICSI) 患者的减数分裂后卵母细胞非整倍性率。我们进行了一项双盲安慰剂对照随机试验，纳入了 35-43 岁的 IVF-ICSI 患者。患者接受 600 毫克 CoQ10 或同等数量的安慰剂帽治疗。我们使用极体活检（PBBX）和比较基因组杂交（CGH）比较了减数分裂后非整倍性率。根据功效计算，每组需要 27 名患者。由于极体活检对胚胎质量和植入影响的安全性担忧，该研究在达到目标参与者人数之前终止。共有 39 名患者接受了评估和随机分组（17 名 CoQ10，22 名安慰剂），27 名患者接受了研究药物（12 名 CoQ10，15 名安慰剂），24 名患者完成了 IVF-ICSI 周期，包括 PBBX 和胚胎移植（10 名 CoQ10，14 名安慰剂）。平均年龄、基线卵泡刺激素 (FSH)、雌二醇和孕酮血清峰值水平以及人类绝经期促性腺激素 (hMG) 单位总数在各组之间没有差异。 CoQ10 组的非整倍体率为 46.5%，而对照组为 62.8%。 CoQ10组的临床妊娠率为33%，对照组的临床妊娠率为26.7%。 CoQ10 组和安慰剂组之间没有发现结果存在显着差异。然而，最终的研究不足以检测非整倍体率的差异。
The age-related reduction in live-birth rate is attributed to a high rate of aneuploidy and follicle depletion. We showed in an animal model that treatment with Coenzyme Q10 (CoQ10) markedly improved reproductive outcome. The aim of this study was to compare the post-meiotic oocyte aneuploidy rate in in vitro fertilization (IVF) and intra cytoplasmic sperm injection (ICSI) patients treated with CoQ10 or placebo. We conducted a double blind placebo controlled randomized trial that included IVF–ICSI patients 35–43 years of age. The patients were treated with either 600 mg of CoQ10 or an equivalent number of placebo caps. We compared the post-meiotic aneuploidy rate using polar body biopsy (PBBX) and comparative genomic hybridization (CGH). According to the power calculation, 27 patients were needed for each arm. Owing to safety concerns regarding the effects of polar body biopsy on embryo quality and implantation, the study was terminated before reaching the target number of participants. A total of 39 patients were evaluated and randomized (17 CoQ10, 22 placebo), 27 were given the study medication (12 CoQ10, 15 placebo), and 24 completed an IVF–ICSI cycle including PBBX and embryo transfer (10 CoQ10, 14 placebo). Average age, base line follicle stimulating hormone (FSH), peak estradiol and progesterone serum level, as well as the total number of human menopausal gonadotropin (hMG) units—did not differ between the groups. The rate of aneuploidy was 46.5% in the CoQ10 group compared to 62.8% in the control. Clinical pregnancy rate was 33% for the CoQ10 group and 26.7% for the control group. No significant differences in outcome were detected between the CoQ10 and placebo groups. However, the final study was underpowered to detect a difference in the rate of aneuploidy.